NUTRIBAND INC (NTRB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:NTRB • US67092M2089

4.36 USD
+0.1 (+2.35%)
Last: Feb 10, 2026, 11:48 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, NTRB scores 4 out of 10 in our fundamental rating. NTRB was compared to 191 industry peers in the Pharmaceuticals industry. While NTRB seems to be doing ok healthwise, there are quite some concerns on its profitability. NTRB is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NTRB has reported negative net income.
  • NTRB had a negative operating cash flow in the past year.
  • In the past 5 years NTRB always reported negative net income.
  • NTRB had a negative operating cash flow in each of the past 5 years.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • NTRB has a worse Return On Assets (-410.87%) than 95.29% of its industry peers.
  • NTRB has a worse Return On Equity (-458.24%) than 79.58% of its industry peers.
Industry RankSector Rank
ROA -410.87%
ROE -458.24%
ROIC N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • The Gross Margin of NTRB (33.50%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of NTRB has remained more or less at the same level.
  • NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NTRB has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NTRB has been increased compared to 5 years ago.
  • Compared to 1 year ago, NTRB has an improved debt to assets ratio.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • NTRB has an Altman-Z score of 25.09. This indicates that NTRB is financially healthy and has little risk of bankruptcy at the moment.
  • NTRB has a better Altman-Z score (25.09) than 90.58% of its industry peers.
  • NTRB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of NTRB (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 25.09
ROIC/WACCN/A
WACC9.45%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M

2.3 Liquidity

  • NTRB has a Current Ratio of 7.53. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 7.53, NTRB is doing good in the industry, outperforming 72.25% of the companies in the same industry.
  • NTRB has a Quick Ratio of 7.35. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.35, NTRB is in the better half of the industry, outperforming 72.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.35
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The earnings per share for NTRB have decreased strongly by -331.58% in the last year.
  • Looking at the last year, NTRB shows a quite strong growth in Revenue. The Revenue has grown by 12.69% in the last year.
  • Measured over the past years, NTRB shows a very strong growth in Revenue. The Revenue has been growing by 41.99% on average per year.
EPS 1Y (TTM)-331.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.78%
Revenue 1Y (TTM)12.69%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%-46.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 100.83% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, NTRB will show a very strong growth in Revenue. The Revenue will grow by 334.01% on average per year.
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • NTRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 2.95, which indicates a rather cheap valuation of NTRB.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NTRB indicates a rather cheap valuation: NTRB is cheaper than 97.91% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.86, NTRB is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 2.95
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • NTRB's earnings are expected to grow with 100.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NTRB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUTRIBAND INC

NASDAQ:NTRB (2/10/2026, 11:48:37 AM)

4.36

+0.1 (+2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-11
Earnings (Next)04-27
Inst Owners3.07%
Inst Owner Change-4.92%
Ins Owners59.53%
Ins Owner Change0%
Market Cap52.45M
Revenue(TTM)2.28M
Net Income(TTM)-34.59M
Analysts82.86
Price Target15.3 (250.92%)
Short Float %5.78%
Short Ratio5.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.73%
Min EPS beat(2)-3.81%
Max EPS beat(2)85.27%
EPS beat(4)2
Avg EPS beat(4)-52.18%
Min EPS beat(4)-316.67%
Max EPS beat(4)85.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-31.62%
Min Revenue beat(2)-49.75%
Max Revenue beat(2)-13.5%
Revenue beat(4)0
Avg Revenue beat(4)-19.02%
Min Revenue beat(4)-49.75%
Max Revenue beat(4)-1.6%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1007.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-80.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.95
P/S 23.02
P/FCF N/A
P/OCF N/A
P/B 6.95
P/tB 9.34
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)1.48
Fwd EY33.92%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.19
BVpS0.63
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -410.87%
ROE -458.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.5%
FCFM N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.3%
Cap/Sales 0.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.35
Altman-Z 25.09
F-Score5
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-331.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.78%
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)12.69%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%-46.42%
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-53.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.72%
OCF growth 3YN/A
OCF growth 5YN/A

NUTRIBAND INC / NTRB FAQ

Can you provide the ChartMill fundamental rating for NUTRIBAND INC?

ChartMill assigns a fundamental rating of 4 / 10 to NTRB.


What is the valuation status for NTRB stock?

ChartMill assigns a valuation rating of 3 / 10 to NUTRIBAND INC (NTRB). This can be considered as Overvalued.


Can you provide the profitability details for NUTRIBAND INC?

NUTRIBAND INC (NTRB) has a profitability rating of 1 / 10.


What is the expected EPS growth for NUTRIBAND INC (NTRB) stock?

The Earnings per Share (EPS) of NUTRIBAND INC (NTRB) is expected to decline by -933.33% in the next year.